Omega-6 fats to prevent and treat heart and circulatory diseases

We included 19 RCTs in 6461 participants who were followed for one to eight years. Seven trials assessed the effects of supplemental GLA and 12 of LA, none DGLA or AA; the omega-6 fats usually displaced dietary saturated or monounsaturated fats. We assessed three RCTs as being at low summary […]


Omega-3 intake for cardiovascular disease

We included 79 RCTs (112,059 participants) in this review update and found that 25 were at low summary risk of bias. Trials were of 12 to 72 months’ duration and included adults at varying cardiovascular risk, mainly in high-income countries. Most studies assessed LCn3 supplementation with capsules, but some used […]


University of British Columbia seeks Faculty Research Associate – Canada

The Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia in Canada seeks applications for a full-time Research Associate in the Therapeutics Section. The successful candidate will lead and conduct a complex systematic review, synthesizing research evidence on the effects of regulatory safety advisories on prescribing, medicine […]


FDA nails Baxter with warning letter for plant picked up in Claris buyout

At exactly the same time that Baxter International was closing its $625 million deal for Claris Injectables last year, FDA inspectors were taking a hard look at one of the three plants Baxter had acquired. Turns out they were not very impressed with its manufacturing processes. The FDA Tuesday posted […]


Janssen's Symtuza scores approval with the FDA in HIV-1

Janssen has announced that Symtuza (D/C/F/TAF) has received approval from the FDA in the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically supressed adult patients, making it the first and only darunavir-based single-tablet regimen available for the disease. The US regulator reached the decision after […]


Roche's Tecentriq extends its hot streak with liver cancer combo breakthrough

Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug—in combination with Roche’s Avastin—picked up a breakthrough therapy designation from the FDA in previously untreated liver cancer patients, putting it on the path to a speedy approval. The agency based the decision on phase 1b data, presented […]


Novartis runs into Kymriah production glitch in new DLBCL indication

Novartis, whose personalized CAR-T cancer treatment Kymriah won an approval in May to treat relapsed large B-cell lymphoma, said today it has run into some manufacturing issues around that condition.   Liz Barrett, CEO of Novartis Oncology, said during the company’s second-quarter earnings call that a majority of patients are getting […]


Evoke Group’s expansion drive continues with West Coast agency buy

Evoke Group has acquired Giant Creative Strategy, adding new geography, expertise and employees as its continues an aggressive growth strategy. The addition of the West Coast full-service healthcare agency adds 150 people to Evoke Group’s roster. The added heft will help to better position Evoke in the competitive pharma and healthcare agency […]


Råd vid värmeböljor

Just nu är det väldigt varmt i stora delar av landet. Höga temperaturer under en längre tid kan vara farligt för alla. Särskilt känsliga för värmen är äldre, kroniskt sjuka, personer med funktionsnedsättning, små barn och gravida samt personer som tar viss medicin. Funderar du över dina mediciner och värmen […]


AstraZeneca increases drug stockpile in preparation for no-deal Brexit

The Anglo-Swedish drug giant AstraZeneca is set to increase its stockpile of drugs in both the United Kingdom and the European Union in preparation for a hard, no-deal Brexit. The Vice President of AstraZeneca’s Global External Manufacturing, Juliette White, told BBC’s Newsnight that:  “Ultimately – and as a safety net […]


Novartis follows Pfizer's lead, pledges no price hikes in 2018

Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the prices of 100 of its products since the beginning of the year, Novartis has followed suit, pledging to freeze any increases in its own pricing until the end of the […]